Alzheimers disease (AD) will become a public health crisis in the very near future if left untreated. There are currently no proven treatments that delay the onset or prevent the progression of AD, although several promising candidates are being tested. During therapy development, it will be critical to have biomarkers that identify individuals at high risk for AD in order to target them for clinical trials and to monitor therapy. Autosomal-dominant AD (ADAD) accounts for a very small proportion of all AD cases (<1%) but the neuropathologic hallmarks and clinical features are similar to the more common sporadic, late-onset form (LOAD). Individuals possessing AD mutations are destined to develop the disease and at a relatively predictable age, thus providing a unique cohort in which to investigate the trajectories/timing of underlying AD pathologies, especially in the preclinical/pre-symptomatic stage. During the initial funding period of DIAN, the Biomarker Core analyzed CSF and plasma samples obtained from participants at baseline, including mutation carriers and non-carriers that fell along a wide spectrum of estimated years to symptomatic onset (EYO). Cross-sectional analyses revealed elevated CSF tau and ptau181, markers of neurodegeneration and/or neurofibrillary tangles, ~15 years prior to the estimated age of symptomatic onset (EAO) (EYO -15). Low levels of CSF A1-42, a marker of amyloid plaques, were observed in carriers ~10 years prior to EAO, but levels appeared to decline much earlier (EYO -25) from levels initially higher than non-carriers. More recent data in DIAN demonstrate the same pattern of elevations in CSF VILIP-1, a tauindependent marker of neurodegeneration, as participants approach their EAO. While these patterns are consistent with what has been reported in cross-sectional studies of LOAD, the trajectory of biomarker changes within individuals as they progress through the disease process is uncertain. With DIAN now evolved to the point of collecting longitudinal samples, we are poised to be able to address this important question. Such information will be critical for the design and evaluation of clinical trials intended to prevent the onset of cognitive decline in at-risk individuals. In the present renewal application, we will build upon our success by:
Aim 1) Maintaining and growing the biorepository of DIAN plasma and CSF samples and coordinating the distribution of samples to qualified investigators for approved studies;
Aim 2) Obtaining fluid analyte measures for evaluation in DIAN crosssectional analyses (including plasma A1-40, Ax-40, A1-42 and Ax-42, CSF A1-42, total tau, and ptau181, and 2 novel biomarker candidates that show robust diagnostic/prognostic utility in LOAD (VILIP-1 and tau seeding activity);and given the critical importance of within-participant analyses in the setting of a biomarker field challenged by limitations in assay stability and reproducibility, Aim 3) Developing and implementing procedures for analysis of longitudinal fluid samples, including analytical protocols and quality control testing.

Public Health Relevance

There are currently no effective treatments that will prevent Alzheimers disease, halt its progression, or delay symptom onset, although several therapeutic approaches are being developed. Elucidating the timing and trajectories of pathology-related biomarkers will aid in disease diagnosis and prognosis and assessing disease risk, especially during the preclinical/asymptomatic period believed to offer the most promise for therapeutic efficacy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Multi-Year Funded Research Project Cooperative Agreement (UF1)
Project #
2UF1AG032438-07
Application #
8863372
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-07-16
Budget End
2019-12-31
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2016) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement :
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0163669
Soosman, Steffan K; Joseph-Mathurin, Nelly; Braskie, Meredith N et al. (2016) Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiol Aging 47:201-209
Lim, Yen Ying; Hassenstab, Jason; Cruchaga, Carlos et al. (2016) BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain 139:2766-2777
Miller-Thomas, Michelle M; Sipe, Adam L; Benzinger, Tammie L S et al. (2016) Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics 36:1147-63
Muenchhoff, Julia; Poljak, Anne; Thalamuthu, Anbupalam et al. (2016) Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. Sci Rep 6:29078
Tang, Mengxuan; Ryman, Davis C; McDade, Eric et al. (2016) Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 15:1317-1325
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0152082
Jin, Yan; Su, Yi; Zhou, Xiao-Hua et al. (2016) Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. EURASIP J Bioinform Syst Biol 2016:12
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2016) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord :

Showing the most recent 10 out of 29 publications